Kinetic modelling of [123I]CNS 1261 - A potential SPET tracer for the NMDA receptor

Nuclear Medicine and Biology

Volumn 30, Issue 4, 2003, Pages 441-454

  Erlandsson, Kjell ^a   Bressan, Rodrigo A ^b   Mulligan, Rachel S ^a   Gunn, Roger N ^c   Cunningham, Vincent J ^d   Owens, Jonathan ^e   Wyper, David ^f   Ell, Peter J ^a   Pilowsky, Lyn S ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e WESTERN INFIRMARY   (United Kingdom)

^f NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Ketamine; Kinetic modeling; MK 801; NMDA receptors; Single photon emission tomography; 123I CNS 1261

Indexed keywords

CARBON 11; CNS 1261; DIZOCILPINE; FLUORINE 18; KETAMINE; LIGAND; MEMANTINE; N (1 NAPHTHYL) N' (3 IODOPHENYL) N METHYLGUANIDINE I 123; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; TRACER; UNCLASSIFIED DRUG; GUANIDINE DERIVATIVE;

ADULT; ARTERY; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; BRAIN REGION; CLINICAL TRIAL; CORPUS STRIATUM; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; FEMALE; HEALTH STATUS; HUMAN; IN VIVO STUDY; MALE; MOLECULAR MODEL; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS; TIME; VEIN; VOLUNTEER; WHITE MATTER; BIOLOGICAL MODEL; BLOOD; BRAIN; METABOLISM; TISSUE DISTRIBUTION;

ADULT; BRAIN; FEMALE; GUANIDINES; HUMANS; MALE; MODELS, BIOLOGICAL; RECEPTORS, N-METHYL-D-ASPARTATE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0038396385     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00450-X     Document Type: Article

References (37)

1. 18F-memantine in healthy volunteers. Nucl Med Biol. 29:2002;227-231.
2. 3H]-MK-801 binding sites in mammalian brain. Br J Pharmacol. 93:1988;944-954.
3. Bressan R.A., Pilowsky L.S. Imaging the glutamatergic system in vivo -relevance to schizophrenia. Eur J Nucl Med. 27:2000;1723-1731.
4. 18F]cyclofoxy and positron emission tomography . J Cereb Blood Flow Metab. 13:1993;24-42.
5. Chang L.-T. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 25:1978;638-643.
6. Cunningham V.J., Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab. 13:1993;15-23.
7. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev. 51:1999;7-61.
8. Friston K.J., Ashburner J., Poline J.B., Frith C.D., Heather J.D., Frackowiak R.S.J. Spatial registration and normalisation of images. Human Brain Mapping. 2:1995;165-189.
9. 125I]Iodo-MK801 to the NMDA receptor-channel complex in rat brain. Nucl Med Biol. 19:1992;319-326.
10. Glick S.J., King M.A., Pan T.-S., Soares E.J. Compensation for nonuniform attenuation in SPECT brain imaging. IEEE Trans Nucl Sci. 43:1996;737-750.
11. Gullberg G.T., Morgan H.T., Zeng G.L., Christian P.E., Di Bella V.R., Tung C.-H., Maniawski P.J., Hsieh Y.-L., Datz F.L. The design and performance of a simultaneous transmission and emission tomography system. IEEE Trans Nucl Sci. 45:1998;1676-1698.
12. Gunn R.N., Gunn S.R., Cunningham V.J. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 21:2001;635-652.
13. 11C]L-703,717, preferentially binds to a cerebellar NMDA receptor subtype consisting of GluR ε3 subunit in vivo, but not in vitro, Synapse. 43:2002;131-133.
14. Hartvig P., Valtysson J., Lindner K.J., Kristensen J., Karlsten R., Gustafsson L.L., Persson J., Svensson J.O., Oye I., Antoni G. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther. 58:1995;165-173.
15. Hu L.Y., Guo J., Magar S.S., Fischer J.B., Burke-Howie K.J., Durant G.J. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N′-(3-substituted phenyl)-N′-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers. J Med Chem. 40:1997;4281-4289.
16. Iida H., Narita Y., Kado H., Kashikura A., Sugawara S., Shoji Y., Kinoshita T., Ogawa T., Eberl S. Effects of scatter and attenuation correction on quantitative assessment of regional cerebral blood flow with SPECT. J Nucl Med. 39:1998;181-189.
17. Kak A.C., Slaney M. Principles of computerized tomographic imaging. 1988;IEEE Press, New York.
18. Kim K.M., Watabe H., Shidahara M., Ishida Y., Iida H. SPECT collimator dependency of scatter and validation of transmission-dependent scatter compensation methodologies. IEEE Trans Nucl Sci. 48:2001;689-696.
19. 11C]Flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab. 11:1991;735-744.
20. Lange K., Fessler J.A. Globally convergent algorithms for maximum a posteriori transmission tomography. IEEE Trans Im Process. 4:1995;1430-1438.
21. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab. 14:1994;453-465.
22. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 10:1990;740-747.
23. 11C]raclopride binding in the brain Model simulations and kinetic analysis of PET data . J Cereb Blood Flow Metab. 14:1994;995-1010.
24. McGregorA.L. Evaluation of a novel non-competitive antagonist as a radioligand for the N-methyl-D-aspartate receptor channel complex in vivo, PhD thesis, University of Glasgow, 1997.
25. 3H]MK-801 binding and the mRNA for the NMDAR1 subunit of the NMDA receptor are differentially distributed in human and rat forebrain. Mol Brain Res. 54:1998;13-23.
26. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 15:1984;217-227.
27. 123I]CNS-1261-A novel NMDA receptor radioligand for SPET. J Labelled Cpd Radiopharm. 44:2001;S228-S230.
28. Narita Y., Eberl S., Iida H., Hutton B.F., Braun M., Nakamura T., Bautovich G. Monte Carlo and experimental evaluation of accuracy and noise properties of two scatter correction methods for SPECT. Phys Med Biol. 41:1996;2481-2496.
29. Ogawa K., Harata Y., Ichihara T., Kubo A., Hashimoto S. A practical method for position-dependent Compton-scatter correction in single emission CT. IEEE Trans Med Im. 10:1991;408-412.
30. Owens J., Wyper D.J., Patterson J., Brown D.R.P., Elliott A.T., Teasdale G.M., McCulloch J. First SPECT images of glutamate (NMDA) receptor activation in vivo in cerebral ischaemia. Nucl Med Comm. 18:1997;149-158.
31. 125I]-CNS 1261) A potential SPECT agent for imaging NMDA receptor activation . Nucl Med Biol. 27:2000;557-564.
32. Reddy N.L., Hu L.Y., Cotter R.E., Fischer J.B., Wong W.J., McBurney R.N., Weber E., Holmes D.L., Wong S.T., Prasad R., Keana J.F.W. Synthesis and structure-activity studies of N,N′-diarylguanidine derivatives. N-(1-naphthyl)-N′-(3-ethylphenyl)-N′-methylguanidine a new, selective noncompetitive NMDA receptor antagonist . J Med Chem. 37:1994;260-267.
33. 18F-MEM) A potential radioligand for mapping the NMDA-receptor complex . Nucl Med Biol. 25:1998;323-330.
34. Sharp F.R., Tomitaka M., Bernaudin M., Tomitaka S. Psychosis pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends in Neurosciences. 24:2001;330-334.
35. Stodilka R.Z., Kemp B.J., Msaki P., Prato F.S., Nicholson R.L. The relative contributions of scatter and attenuation corrections toward improved brain SPECT quantification. Phys Med Biol. 43:1998;2991-3008.
36. Stodilka R.Z., Kemp B.J., Prato F.S., Nicholson R.L. Importance of bone attenuation in brain SPECT quantification. J Nucl Med. 39:1998;190-197.
37. Talairach J., Tournoux P. Co-planar stereotactic atlas of the human brain. 1988;Thieme Medical, New York.